Semaglutide (Ozempic, Wegovy, Rybelsus)
Semaglutide is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction in adults with established cardiovascular disease or with obesity/overweight. Landmark 2023–2024 evidence (SELECT, FLOW) extended its role into secondary CV prevention and diabetic kidney disease.
- Mechanism of action
- Long-acting GLP-1 receptor agonist that augments glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite.
- Administration route
- Subcutaneous injection (Ozempic, Wegovy) and oral tablet (Rybelsus)
FDA-approved indications (2026)
Type 2 diabetes mellitus
Glycemic control in adults as adjunct to diet and exercise (Ozempic, Rybelsus).
Cardiovascular risk reduction in T2DM
Reduction of major adverse cardiovascular events (MACE) in adults with T2DM and established CV disease (Ozempic; SUSTAIN-6).
Chronic weight management
Wegovy for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity; pediatric indication for age ≥12 with obesity.
Cardiovascular risk reduction without diabetes
Wegovy is indicated to reduce MACE in adults with established CV disease and either obesity or overweight (SELECT 2023).
Chronic kidney disease in T2DM
Reduction of kidney disease progression and CV death in T2DM + CKD, supported by FLOW (2024).
Dosing: adult, renal, and hepatic
| Population | Dose |
|---|---|
| T2DM — Ozempic | Start 0.25 mg SC weekly × 4 wk → 0.5 mg weekly; may titrate to 1 mg, then 2 mg weekly. |
| Weight management — Wegovy | Escalate monthly: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg SC weekly (maintenance 2.4 mg). |
| Oral — Rybelsus | 3 mg PO daily × 30 days → 7 mg; may increase to 14 mg. Take fasting with ≤4 oz water, 30 min before food/other meds. |
| Renal impairment | No dose adjustment (including dialysis); monitor hydration in diarrhea/vomiting. |
| Hepatic impairment | No dose adjustment. Limited data in severe hepatic impairment. |
Contraindications and boxed warnings
Contraindications
- Personal or family history of medullary thyroid carcinoma.
- Multiple endocrine neoplasia syndrome type 2 (MEN2).
- Prior serious hypersensitivity to semaglutide.
Boxed warnings
- Risk of thyroid C-cell tumors in rodents; human relevance unknown.
2026 guideline and pivotal trial position
ADA 2026 Standards of Care position GLP-1 RAs, including semaglutide, as first-line injectable therapy for T2DM when ASCVD, HF, or CKD is present, and co-recommends them with SGLT2 inhibitors where CV/renal benefit is the priority. The AHA 2024 scientific statement and subsequent 2025 guidance endorse semaglutide 2.4 mg for secondary CV prevention in patients with overweight/obesity based on SELECT. KDIGO 2024 incorporates GLP-1 RAs into the diabetic kidney disease care algorithm following FLOW.
SUSTAIN-6
26% relative risk reduction in MACE over 2.1 years in T2DM with CVD risk.
STEP 1–8
Chronic weight management — ~15% mean weight loss at 68 weeks with 2.4 mg.
SELECT (NEJM 2023)
20% reduction in composite MACE in non-diabetic adults with established CVD + overweight/obesity.
FLOW (2024)
24% reduction in composite kidney/CV outcome in T2DM + CKD; trial stopped early for efficacy.
Cross-system reasoning
Semaglutide is an example of a cardiometabolic-renal agent whose decision calculus crosses endocrinology, cardiology, and nephrology. In a patient with T2DM, LVEF-preserved heart failure, CKD stage 3, and obesity, semaglutide plus an SGLT2 inhibitor layers CV protection (SELECT, SUSTAIN-6), renal protection (FLOW), and weight reduction without compounding hypoglycemia risk. Practical cross-system caveats: delayed gastric emptying complicates perioperative airway management (ASA 2023 guidance — held 1 wk preop for injectable formulations), and persistent GI symptoms warrant evaluation for gastroparesis or cholelithiasis.
Key references
Related clinical reading
Explore Semaglutide in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
This reference is for US-licensed physicians and is not a substitute for the full FDA prescribing information. Dosing in special populations, drug interactions, and emerging safety information should be verified against the current manufacturer label and society guidelines before prescribing.